Omada Health reported that participants in its 12‑week GLP‑1 Care Track program lost an average of 6.0% of starting weight, 1.8 times the 3.3% weight loss seen in a control group of adults with obesity who had recently begun GLP‑1 medication. The study, which followed 245 adults, also found that Omada members reduced body‑fat percentage by 3.3%, twice the 1.6% reduction observed in controls, and increased muscle‑mass percentage by nearly three times, indicating that the program mitigates the lean‑mass loss commonly associated with GLP‑1 therapy.
The control group was not a passive comparison; more than a quarter of its members reported participation in non‑Omada wellness programs, yet they still achieved lower weight‑loss and body‑fat reduction outcomes. While the study did not disclose statistical significance levels, the magnitude of the differences suggests a robust effect of the behavioral platform on composition‑specific weight loss.
Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health, said, “Too often, patients are prescribed GLP‑1s and left on their own with vague advice to make lifestyle changes to meet their goals and improve their health. Omada is designed to not only support members through their whole GLP‑1 treatment journey, but to also increase the quality of the weight loss. Instead of only changing the number on the scale, the Omada program has demonstrated that it can change what that number is made of: more fat loss, preserved muscle, and better daily functioning.”
These findings reinforce Omada’s value proposition to payers and employers, positioning the company to expand coverage of its companion‑care program and strengthen its competitive moat in the rapidly growing GLP‑1 market. The study’s results also align with Omada’s recent financial trajectory: Q4 2025 revenue rose 58% YoY to $76 million, the company achieved its first GAAP‑profitable quarter, and FY 2025 revenue reached $260 million, up 53% YoY. Gross margins improved to 71% GAAP and 73% non‑GAAP in Q4 2025, up from 67% and 69% respectively in Q4 2024. Management has guided 2026 revenue to $312 million–$322 million, a 22% increase, reflecting confidence in continued demand for its digital health platform.
The study’s demonstration of superior weight loss and muscle preservation provides evidence that Omada’s behavioral intervention can enhance the effectiveness of GLP‑1 therapy, potentially accelerating payer and employer adoption and driving future revenue growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.